Business
HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology
Company Continues Expanding its Intellectual Property Footprint, Now has 14 US and 4 International Patents SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam,
About this update from Heartbeam, Inc.
[{"type":"text","content":"\nCompany Continues Expanding its Intellectual Property Footprint, Now has 14 US and 4 International Patents\n\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office. HeartBeam now has 14 issued and allowed US patents and 4 international patents for its VECG technology which collects 3D signals of the heart and converts them into a 12-lead ECG.\n\n\n“HeartBeam’s core VECG technology is designed to be used with portable, patient-friendly devices such as a credit-card sized system, an extended wear patch, or watch to enable physicians to monitor patients and identify cardiac health trends outside of a medical facility,” said Branislav Vajdic, PhD, CEO and Founder of HeartBeam. “These new patents reinforce our strategic vision which is founded on developing and protecting our novel VECG technology and product pipeline as we work to transform how cardiac care is delivered in the future.”\n\n\nThe first patent, “Mobile three-lead cardiac monitoring device and method for automated diagnostics” covers apparatuses and methods that facilitate the comparison of cardiac signals over time for the automated or assisted detection of heart attacks, or Acute Myocardial Infarction (AMI). For each patient, HeartBeam provides a comparative baseline ECG which aids physicians in gaining richer insights about the patient’s cardiac health. This approach was validated in a landmark JACC: Advances publication which demonstrated that HeartBeam’s VECG approach with a comparative baseline had significantly higher diagnostic accuracy (95% Area Under the Curve or AUC) than a 12-lead ECG alone (68% AUC).\n\n\nThe second patent, “Apparatus for generating an electrocardiogram” covers methods and apparatuses around HeartBeam’s wrist-based ECG system. This is the second patent related to HeartBeam’s watch concept, which combines a continuous ECG monitor with the ability to take a high sensitivity 12-lead ECG – all in a single device designed to be worn on the wrist.\n\n\nIn addition to the 14 issued and allowed US patents and 4 international patents, HeartBeam has 20 pending ap...